ArticleThe Iowa orthopaedic journal2026
A Contemporary Analysis of Corticosteroid Injections in Patients with Mild, Moderate, and Severe Hip Osteoarthritis: High Risk, Low Reward.
Article in The Iowa orthopaedic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hip osteoarthritis (HOA) represents a leading cause of disability in the United States. Consequently, intraarticular corticosteroid injections (lACSIs) are routinely recommended and utilized for non-surgical management of symptomatic HOA. While they are shown to decrease pain intensity, few studies have reported on the potential risk of rapidly progressive osteoarthritis (RPOA). This study aimed to assess the rate of HOA progression following IACSI in patients with mild, moderate, and severe HOA. Methods: This single-institution study retrospectively reviewed patients who underwent image-guided IACSI for HOA between January 1, 2022 and January 1, 2023, with a minimum follow-up of two years. Pre-injection and post-injection radiographs were reviewed to assign HOA grades (0-4) using the Kellgren-Lawrence (KL) classification system. Patients with mild, moderate, and severe (KL 2-4) HOA on pre-injection radiographs were included. Primary outcomes included changes in post-injection KL grades and time-to-total hip arthroplasty (THA). Results: There were 560 patients included, with an average age of 66.7 years, a mean BMI of 30.1, and 59.5% women. For patients with pre-injection KL grade < 4 (i.e., mild and moderate HOA or KL grades 2 and 3), there was HOA progression of one level in 185 (45.7%) patients. In the 147 (26.3%) patients with a pre-injection KL grade < 3 (i.e., mild HOA or KL grade 2), 32 (21.8%) increased by two levels. From the total cohort, 491 (87.6%) patients ultimately underwent THA. The average time-to-THA was 206 ± 95.6 days. There were no significant differences between pre-injection and post-injection patient-reported outcomes (PROs). Conclusion: Radiographic comparisons before and after IACSI revealed concerning HOA progression in over half the patients without severe HOA. Combined with a minimal change in PROs and most patients electing to undergo THA within the following months, the safety and utility of IACSI in this population must be reconsidered. Level of Evidence: III.
Indexed as
Identifiers
42488311PMC13389362What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.